Navigation Links
SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
Date:9/16/2008

ourth quarter of 2008. Prior to proceeding with the trial the company must await clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. SemBioSys' planned Phase I/II human clinical trial is designed to enroll up to 30 healthy volunteers in a three-arm study to demonstrate the bioequivalence of safflower-produced insulin to comparator insulin products. The European authorities are the first major healthcare regulators to have published guidance documents that ensure insulin is eligible to receive approval through an abbreviated regulatory path. Separately, the U.S. FDA has advised SemBioSys that safflower-produced insulin is eligible to receive approval through an abbreviated 505(b)(2) approval process.

The world market value for insulin is estimated to be in excess of US$7.1 billion today and the demand for insulin is projected to increase due to two factors. The growing incidence of diabetes combined with the expanded use of insulin therapy is expected to almost double insulin demand over the next five years and increase the global insulin market to over $15 billion by 2012. SemBioSys' plant-made insulin is expected to offer substantial capital and cost-of-goods reductions with the potential to enter the market as a low-cost, easily expandable source of insulin to meet exploding global demand.

About SemBioSys Genetics Inc.

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AIMilano, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys and its subsidiary, Botaneco Specialty Ingredients Inc., are developing a series of non-pharmaceutical products addressing human topical, nutritional
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys updates Apo AI development program
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys announces 2007 third quarter results
4. SemBioSys signs option agreement for safflower-produced food ingredient
5. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
6. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
7. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys initiates toxicology study for safflower-produced insulin
10. SemBioSys receives milestone payments from AVAC Ltd.
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Women in the ... to an additional family planning option. Sayana® Press ... at all levels of the health system and ... a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with ... is the first of four African countries expected ...
(Date:7/10/2014)... 2014 Product and process impurities ... abundance and are often “lost in the noise,” ... Join presenters Dr. Rowel Tobias, Senior Scientist, Protein ... Head of Quality at Nanotherapeutics, Inc., to lear ... speed detection and quantitation while achieving the required ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... Cleveland, Ohio (PRWEB) July 10, 2014 ... in ion channel-expressing cell lines, and the gap that ... new cells that expand its industry-leading portfolio of validated ... focuses on ion channel-expressing cell lines, as ion channels ... able to control this activity creates the potential to ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... 13 Nile Therapeutics, Inc.,(Nasdaq: NLTX ), today ... present at the Rodman & Renshaw 5th Annual Global ... at Le Meridian Beach,Plaza Hotel in Monte Carlo, Monaco. ... the status of Nile,s current clinical development,programs., The ...
... Foamix Offers New Intravaginal Foam Technology with Improved Usability & ... ... Israel, May 13 Despite the high incidence,of women,s health conditions ... and ovules, a recent survey,found that an alarming majority of women ...
... with CelVida Yields First Milestone, NEW YORK, May ... pioneering the pre-disease collection, processing and long-term,storage of adult ... a,site has been secured for a new stem cell ... Robin Smith, MD MBA, NeoStem,s Chairman and Chief ...
Cached Biology Technology:Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 272% of Women Are Dissatisfied With Their Current Treatment of Vaginal Infection, Survey Finds 2NeoStem to Expand Stem Cell Collection Center Network to Florida 2NeoStem to Expand Stem Cell Collection Center Network to Florida 3
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... , June 27, 2014  The American ... National Institute of Standards and Technology (NIST) and ... its academic research and forensic science expert members ... Board is an element of the NIST,s Organization ... are among the first appointments made to the ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... for a University of Alberta paleontology researcher, who after months of ... as a new species of pterosaur, a flying reptile that lived ... stumped when the small piece of jaw bone was first pulled ... A,s paleontology department. "It could have been from a dinosaur, ...
... 4, 2011) − Scientists at the University of Kentucky have ... break up blood clots, speeds up the progress of prion ... plasminogen a promising new target for the development of drugs ... senior author Chongsuk Ryou, a researcher at the UK Sanders-Brown ...
... Lithuania, Jan. 10, 2011 Neurotechnology , ... announced the release of MegaMatcher 4.0 , ... fingerprint, iris, facial and palmprint biometrics in a ... MegaMatcher 4.0, Neurotechnology has incorporated palmprint technology along ...
Cached Biology News:Research identifies drug target for prion diseases, 'mad cow' 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 3
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
B-FABP (FL-132)...
Roll of Mesh 5m x 25cm...
Biology Products: